OR-GUROBI-OPTIMIZATION
Gurobi Optimization, LLC , creator of the world’s fastest mathematical optimization solver, today announced the release of Gurobi Optimizer 9.5. This release provides customers with an even faster compute engine, with impressive performance improvements across all supported problem types.
Gurobi 9.5 also includes new features that make it well suited for enterprise use, including:
- Seamless Docker Deployments: Run Gurobi in container environments, easily, with the Gurobi Web License Service (WLS).
- User-Level Management: Manage users and assign permission levels in a centralized location, by integrating Gurobi Compute Server and Cluster Manager with LDAP repositories.
- Better API Key Management: Label API keys with descriptive information in the Cluster Manager to simplify API key tracking and management.
Customers will discover over a dozen enhancements across the product, such as native support for Apple M1, powerful new heuristics for non-convex quadratic models, norm constraints, deterministic work measures, memory limit parameters, and more user control of IIS computation, as well as improvements to callbacks and tuning.
“I’m confident that our customers will be really pleased with Gurobi 9.5. And happy customers are the foundation upon which our whole business is built,” said Dr. Edward Rothberg, Chief Executive Officer and Co-founder of Gurobi Optimization.
Gurobi 9.5 also showcases the company’s continued support for Python—the most popular programming language in the world—with an improved Python interface and support for Python 3.10.
“One of the most challenging parts of running a modern business is managing complexity. Every decision you make affects other decisions. With Gurobi Optimizer, you can explore all the possibilities and all the implications—and identify your best course of action, in seconds,” added Dr. Rothberg.
“Even though the Gurobi Optimizer is the fastest mathematical optimizer in the world, we’re not going to rest on our laurels. We will keep pushing to improve and innovate because we’re passionate about mathematical optimization and the difference it makes in solving real-world problems,” said Dr. Tobias Achterberg, Vice President of Research and Development (R&D) at Gurobi Optimization.
The team’s commitment to continual improvement is evident in the performance numbers. Gurobi Optimizer 9.5 has boosted its speeds across the board, including:
- Primal Simplex: 23% faster overall, 43% faster on hard models
- Dual Simplex: 20% faster overall, 43% faster on hard models
- Barrier : 18% faster overall, 56% faster on hard models
- Concurrent LP: 14% faster overall, 54% faster on hard models
- MIP : 15% faster overall, 27% faster on hard models
- Convex MIQP : 30% faster overall, 68% faster on hard models
- Convex MIQCP : 33% faster overall, 78% faster on hard models
- Non-Convex MIQCP : 3.0x faster overall, 7.5x faster on hard models
“Our customers rely on us for solving extremely complex challenges. Our technology makes that possible. But our secret sauce is our team of specialists and PhDs, as well as our partner network. These are the people who make Gurobi come to life—working closely with our customers and helping them succeed,” added Dr. Achterberg.
To learn more about Gurobi 9.5, please visit https://www.gurobi.com/9.5 .
About Gurobi Optimization
Gurobi produces the world’s fastest and most powerful mathematical optimization solver – the Gurobi Optimizer – which is used by leading global companies across more than 40 different industries to rapidly solve their complex, real-world problems and make automated decisions that optimize their efficiency and profitability. As the market leader in mathematical optimization software, we aim to deliver not only the best solver, but also the best support – so that companies can fully leverage the power of mathematical optimization (on its own or in combination with other AI techniques such as machine learning) to drive optimal business decisions and outcomes.
Founded in 2008, Gurobi has operations across the USA, Europe, and Asia and has more than 2,500 customers globally including SAP, Air France, Uber, and the National Football League (NFL). For more information, please visit https://www.gurobi.com/ or call +1 713 871 9341.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211116005125/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom